183 related articles for article (PubMed ID: 34520399)
21. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
[TBL] [Abstract][Full Text] [Related]
22. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
[TBL] [Abstract][Full Text] [Related]
23. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
24. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
25. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
26. HSD3B1 is a specific trophoblast-associated marker not expressed in a wide spectrum of tumors.
Chou YY; Jeng YM; Mao TL
Int J Gynecol Cancer; 2013 Feb; 23(2):343-7. PubMed ID: 23318910
[TBL] [Abstract][Full Text] [Related]
27. Equine fetal adrenal, gonadal and placental steroidogenesis.
Legacki EL; Ball BA; Corbin CJ; Loux SC; Scoggin KE; Stanley SD; Conley AJ
Reproduction; 2017 Oct; 154(4):445-454. PubMed ID: 28878092
[TBL] [Abstract][Full Text] [Related]
28. Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women.
Zeleniuch-Jacquotte A; Toniolo P; Levitz M; Shore RE; Koenig KL; Banerjee S; Strax P; Pasternack BS
Cancer Epidemiol Biomarkers Prev; 1995 Dec; 4(8):857-60. PubMed ID: 8634657
[TBL] [Abstract][Full Text] [Related]
29. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Dudenkov TM; Ingle JN; Buzdar AU; Robson ME; Kubo M; Ibrahim-Zada I; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Barman P; Goetz MP; Northfelt DW; Moreno-Aspita A; Williard CV; Kalari KR; Nakamura Y; Wang L; Weinshilboum RM
Breast Cancer Res Treat; 2017 Jul; 164(1):189-199. PubMed ID: 28429243
[TBL] [Abstract][Full Text] [Related]
30. Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Friesenhengst A; Pribitzer-Winner T; Miedl H; Pröstling K; Schreiber M
Horm Cancer; 2018 Apr; 9(2):128-138. PubMed ID: 29363090
[TBL] [Abstract][Full Text] [Related]
31. Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy.
Shimodaira M; Nakayama T; Sato I; Sato N; Izawa N; Mizutani Y; Furuya K; Yamamoto T
Endocrine; 2012 Dec; 42(3):700-7. PubMed ID: 22638611
[TBL] [Abstract][Full Text] [Related]
32. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
Suzuki R; Ye W; Rylander-Rudqvist T; Saji S; Colditz GA; Wolk A
J Natl Cancer Inst; 2005 Nov; 97(21):1601-8. PubMed ID: 16264180
[TBL] [Abstract][Full Text] [Related]
33. An Estrogen-Related Dietary Pattern and Postmenopausal Breast Cancer Risk in a Cohort of Women with a Family History of Breast Cancer.
Guinter MA; Sandler DP; McLain AC; Merchant AT; Steck SE
Cancer Epidemiol Biomarkers Prev; 2018 Oct; 27(10):1223-1226. PubMed ID: 30232064
[No Abstract] [Full Text] [Related]
34. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.
Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Wolk A
Int J Cancer; 2006 Oct; 119(7):1683-9. PubMed ID: 16646051
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II triggers expression of the adrenal gland zona glomerulosa-specific 3β-hydroxysteroid dehydrogenase isoenzyme through de novo protein synthesis of the orphan nuclear receptors NGFIB and NURR1.
Ota T; Doi M; Yamazaki F; Yarimizu D; Okada K; Murai I; Hayashi H; Kunisue S; Nakagawa Y; Okamura H
Mol Cell Biol; 2014 Oct; 34(20):3880-94. PubMed ID: 25092869
[TBL] [Abstract][Full Text] [Related]
36. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
37. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
[TBL] [Abstract][Full Text] [Related]
38. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.
Fourkala EO; Zaikin A; Burnell M; Gentry-Maharaj A; Ford J; Gunu R; Soromani C; Hasenbrink G; Jacobs I; Dawnay A; Widschwendter M; Lichtenberg-Fraté H; Menon U
Endocr Relat Cancer; 2012 Apr; 19(2):137-47. PubMed ID: 22199143
[TBL] [Abstract][Full Text] [Related]
39. Human placental 3β-hydroxysteroid dehydrogenase/steroid Δ5,4-isomerase 1: Identity, regulation and environmental inhibitors.
Zhu Q; Pan P; Chen X; Wang Y; Zhang S; Mo J; Li X; Ge RS
Toxicology; 2019 Sep; 425():152253. PubMed ID: 31351905
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
